CLINICAL TRIAL: VACCINATION WITH HER-2/NEU AND CEA PEPTIDES IN COLORECTAL CANCER

临床试验：HER-2/NEU 和 CEA 肽疫苗接种治疗结直肠癌

• 批准号: 7718608
• 负责人: EUGENE F FOLEY
• 金额: $ 1.47万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718608
• 关键词: Adjuvant; Autologous; Clinical Trials; Colon Carcinoma; Colorectal Cancer; Computer Retrieval of Information on Scientific Projects Database; Cytotoxic T-Lymphocytes; Funding; Grant; Granulocyte-Macrophage Colony-Stimulating Factor; Institution; Patients; Peptides; Protocols documentation; Research; Research Personnel; Resources; Source; Staging; United States National Institutes of Health; Vaccination; Vaccines; design; immunogenic; immunogenicity; neoplastic cell; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol is designed to assess the immunogenicity of a vaccine comprised of four colon cancer peptides plus GM-CSF in adjuvant in patients with Stage II, III, or IV colorectal cancer. The objectives of this study are to determine if the vaccine is:(a) safe, (b) immunogenic, and (c) induces cytotoxic T-cell responses against autologous and/or MHC-matched tumor cells.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本方案旨在评估由四种结肠癌肽加上GM-CSF佐剂组成的疫苗在II、III或IV期结肠直肠癌患者中的免疫原性。 本研究的目的是确定疫苗是否：（a）安全，（B）免疫原性，和（c）诱导针对自体和/或MHC匹配肿瘤细胞的细胞毒性T细胞应答。